Josh Hardman

Josh Hardman is the founder and editor of Psychedelic Alpha, an independent media and consultancy firm devoted to the psychedelics industry. From business and drug development through to policy reform and scientific research. Using data-driven reporting, analysis and commentary, Hardman strives to empower individuals with the knowledge, network and nuance to make an impact within the emerging field of psychedelic medicine and beyond. Hardman has authored hundreds of analyses on topics broadly related to psychedelic business, policy and research, such as commercialisation, IP and regulation. He has spoken about psychedelic drug development and industry at conferences worldwide and acted as an expert witness to bodies such as the European Parliament and the Dept. of Health and Human Services.

The state of the psychedelic industry

Psychedelic Alpha Editor Josh Hardman takes you on a whistle-stop tour of the psychedelics industry: from the basics of the value chain, funding dynamics and drug development pipeline through to policy reform efforts, pre-approval access pathways and key trends. He ends by providing a look ahead to select challenges and questions that the field must grapple with, before turning to audience questions. If Hardman can’t answer your question, he vows to do his best to connect you with someone who can!